Trial of new Covid treatment yields encouraging results

A SINGLE-INJECTION antiviral treatment for newly-infected Covid-19 patients reduced the risk of hospitalisation by half in a large-scale clinical trial, according to a study published yesterday.

Stanford University professor Jeffrey Glenn, coauthor of the study published in the New England Journal of Medicine (NEJM), said the new drug “showed profound benefits for vaccinated and unvaccinated people alike.”